- Home
- LAES vs ENGN Comparison
LAES vs ENGN Comparison
Compare LAES & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LAES | ENGN |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.0M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LAES | ENGN |
|---|---|---|
| Price | $4.24 | $8.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 14.3M | 528.5K |
| Earning Date | 12-11-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,978,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $2.65 |
| 52 Week High | $11.00 | $11.14 |
Technical Indicators
Market Signals| Indicator | LAES | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 55.12 |
| Support Level | $4.45 | $7.77 |
| Resistance Level | $5.09 | $8.49 |
| Average True Range (ATR) | 0.38 | 0.61 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 33.59 | 66.45 |
Price Performance
Historical ComparisonAbout LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.